A National Institutes of Health study will evaluate whether to screen tens of thousands of healthy infants for genetic ...

What if we could prevent people from developing obesity? The World Obesity Federation expects more than half the global population to develop overweight or obesity by 2035. However, treatment ...

Utilize Guardant’s portfolio of liquid biopsy tests in Pfizer’s global clinical studies. Evaluate the clinical utility of (a) circulating tumor DNA (ctDNA) level as a surrogate endpoint to monitor ...

SEATTLE — Molecular testing has been widely integrated into mainstream healthcare, and its use is increasing in dermatology. It can help differentiate between skin conditions, for example, as some ...

Intensity of End-of-Life Care in a Cohort of Commercially Insured Women With Metastatic Breast Cancer in the United States To identify the approximately 12% with inherited cancer predisposition, all ...

For Josh Henderson, 66, of Olympia, getting genetic testing was a no-brainer. “The first time I came to Fred Hutch, my oncologist suggested it,” said the retired IT manager who received a metastatic ...

Breaking news and analysis from time.com. Politics, world news, photos, video, tech reviews, health, science, and entertainment news.

Pfizer and 3SBio's PD-1xVEGF deal, the FDA's first approval for an Alzheimer's disease blood test and Samsung Biologics' planned spinoff of Samsung Bioepis made our ...

Scientists at Northwestern Medicine have developed a new genetic risk score that predicts who is most likely to experience irregular or dangerous heart rhythms. The test merges several types of ...

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its ultra-sensitive Signatera Genome assay is now broadly ...

Drs Kevin Alexander and Joban Vaishnav explore when and how to use genetic testing in ATTR-CM, why distinguishing hereditary from wild-type disease matters, and what this means for patients' families.

The National Comprehensive Cancer Network recommends germline genetic testing for patients with prostate cancer and high-risk features or a suggestive family history. In 2024, the University of ...